
    
      the investigators will evaluate the overall response rate (complete and partial responses) in
      first-line treatment failure or relapse after first-line therapy SCLC treated with Pegylated
      liposomal doxorubicin and ifosfamide We will evaluate the progression-free survival (PFS) and
      overall survival (OS) i in receiving first-line treatment failure or relapse after first-line
      therapy SCLC treated with Pegylated liposomal doxorubicin and ifosfamide
    
  